Each enteric coated tablet contains Rabeprazole Sodium USP 20 mg.
Rabeprazole suppresses gastric and secretion by inhibiting the gastric H+/K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell. Rabeprazole has been characterized as a gastric proton-pump inhibitor.
Route of administration: Oral.
Rabizol tablet should be swallowed whole. Rabizol tablet can be taken with or without food.
Healing of Erosive or Ulcerative GERD:
The recommended adult oral dose is 1 Rabizol tablet to be taken once daily for 4 to 8 weeks. For those patients who have not healed after 8 weeks or treatment, an additional 8-week course of Rabizol tablet may be considered.
Maintenance of Healing of Erosive or Ulcerative GERD:
The recommended adult oral dose is one Rabizol tablet once daily.
Treatment of Symptomatic GERD:
The recommended adult oral dose is 1 Rabizol tablet once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, and additional course of treatment may be considered.
Healing of Duodenal Ulcers:
The recommended adult oral dose is 1 Rabizol tablet once daily after the morning meal for a period up to 4 weeks. Most patients with duodenal ulcer heal within 4 weeks. A few patients may require additional therapy to achieve healing.
Helicobacter pylori Eradication to Reduce the risk of Duodenal Ulcer Recurrence:
Rabeprazole.
20 mg.
Twice daily with the morning and evening meals for 7 days.
Amoxicillin.
1000 mg.
Clarithromycin.
500 mg.
Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome:
The dosage of Rabizol tablet in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Dose should be adjusted to individual patients need and should continue for as long as clinically indicated. Some patients may require divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with Rabizol tablet for up to one year.
Or as Directed by the Registered Physician.:
Rabeprazole like other PPIs is metabolized through Cytochrome P450 drug metabolizing enzyme system. But Rabeprazole does not have clinically significant interaction with other drug metabolized by CYP450 system, such as warfarin, theophylline, diazepam and phenytoin. Rabeprazole inhibits gastric acid secretion and may interfere with absorption of drugs were gastric pH is an important determinant of bioavailability e.g. Ketoconazole, iron salts and digoxin. In studies no interaction with liquid antacid or foods was observed.
Overdose:
There has been no experience with large overdoses with Rabeprazole. In the event of overdose, treatment should be symptomatic and supportive.
Pregnancy: Pregnancy category B. There are no adequate well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.
Lactation: Since many drugs are excreted in milk and because of the potential for adverse reactions to nursing infants for Rabeprazole, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals can not be ruled out.
Administration of Rabeprazole to patients with mild to moderate liver impairment results in increased exposure and decreased elimination. Caution should be exercised in patients with severe hepatic impairment.
Store below 30°C temperature & dry place, protect from light. Keep all medicine out of reach of the children.